Clinical Trial Update: A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II study evaluating safety and efficacy of TQB2450 injection in relapsed or refractory classical Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Safety and Effectiveness | Phase 2 | Status: UNKNOWN